Barclays
RVMD icon

Barclays’s Revolution Medicines RVMD Stock Holding History

Barclays’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-25,000
Closed -$806K – 5242
2024
Q1 		$806K Buy
+25,000
New +$741K ﹤0.01% 3283

Other funds holding RVMD

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Barclays's RVMD Position: Q1 2026 in Review

Barclays increased its Revolution Medicines (RVMD) stake by 182% in Q1 2026, buying an estimated $25M and bringing the position to 383,179 shares worth $37.3M. The position accounts for 0.01% of the portfolio, ranked #838.

Barclays first reported a position in RVMD in Q1 2022 and has held it in 17 quarters since. 512 funds tracked by Wall St. Rank hold RVMD as of Q1 2026.

  • Barclays held 383,179 shares of Revolution Medicines worth $37.3M as of Q1 2026.
  • Barclays bought 247,131 Revolution Medicines shares in Q1 2026, an estimated $25M.
  • Revolution Medicines made up 0.01% of Barclays's portfolio in Q1 2026, its #838 holding.
  • Barclays first reported a position in Revolution Medicines in Q1 2022 and has held it in 17 quarters since.
  • 512 funds tracked by Wall St. Rank held Revolution Medicines as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.